You are viewing: India Radioligand Therapy (RLT) Market analysis

The India Radioligand Therapy (RLT) Market was valued at $0 Million in 2025 and projected to reach to $14.21 Million by 2030, representing a compound annual growth rate of . India's radioligand therapy market is positioned at an inflection point, transitioning from a nascent stage to rapid commercialization through 2030.

India Radioligand Therapy (RLT) Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Radioligand Therapy (RLT) Market Trends and Insights

  • Although India's RLT market was nascent in 2025, the country is experiencing accelerated adoption driven by increasing cancer prevalence, growing healthcare infrastructure investments, and rising awareness of targeted nuclear medicine therapies.
  • India's pharmaceutical and healthcare sectors are rapidly integrating advanced diagnostic and therapeutic modalities, positioning radioligand therapy as a critical component of precision oncology strategies. The trajectory from 2025 to 2030 reflects India's commitment to modernizing cancer treatment protocols and expanding access to innovative therapies.
  • India's regulatory environment, led by the Central Drugs Standard Control Organization (CDSCO), is increasingly supportive of nuclear medicine approvals and clinical trials.
  • Healthcare providers across India's major metropolitan centers and emerging medical hubs are investing in cyclotron infrastructure and radiopharmaceutical manufacturing capabilities to support RLT deployment.
  • This market evolution underscores India's transition toward value-based, precision-driven oncology care aligned with global standards..

Key Market Statistics

  • CAGR (2025-2030)
  • Market Size, 2025 ~USD 0 Million
  • Forecast, 2030 ~USD 14.21 Million
  • Country India

India Radioligand Therapy (RLT) Market Overview

Nascent Market with High Growth Potential :

India's RLT market is projected to grow from USD 0 million in 2025 to USD 14.21 million by 2030, representing a transformative expansion phase driven by increasing adoption of targeted nuclear medicine therapies in oncology treatment protocols.

Rising Cancer Burden Driving Demand :

India's escalating cancer prevalence, coupled with growing patient awareness of advanced treatment options, is creating substantial demand for radioligand therapy as a precision medicine solution for various malignancies.

Healthcare Infrastructure Modernization :

Significant investments in nuclear medicine facilities, cyclotrons, and radiopharmaceutical production capabilities across major Indian cities are establishing the foundational infrastructure necessary for RLT market expansion.

Regulatory and Clinical Adoption Momentum :

Increasing regulatory approvals, clinical trial initiatives, and physician training programs in India are accelerating the clinical adoption and integration of radioligand therapy into mainstream oncology treatment pathways.

India Radioligand Therapy (RLT) Market Dynamics

  • The convergence of rising cancer incidence, enhanced healthcare spending, and growing physician familiarity with targeted nuclear medicine is catalyzing market expansion.
  • Government initiatives promoting advanced cancer care and private sector investments in radiopharmaceutical infrastructure are strengthening market fundamentals. The forecast period will witness accelerated adoption across metropolitan and tier-2 cities, supported by improved patient access and reimbursement pathways.
  • Strategic partnerships between international RLT manufacturers and Indian healthcare providers, combined with localized production capabilities, will drive market penetration.
  • By 2030, India is expected to emerge as a significant RLT market within the Asia-Pacific region, reflecting the country's growing role in precision oncology..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • India's RLT market is projected to reach USD 14.21 million by 2030, reflecting rapid market emergence and adoption of advanced nuclear medicine therapies.
      • India's growing cancer burden and expanding healthcare infrastructure are primary catalysts driving radioligand therapy adoption across oncology centers.
      • India's regulatory framework and cyclotron infrastructure investments are enabling domestic radiopharmaceutical manufacturing and clinical trial expansion.
      • India's precision oncology transition positions RLT as a high-value therapeutic option for neuroendocrine, prostate, and other targeted cancer indications.

      Radioligand Therapy (RLT) Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment [LU-177]-PNT2002 (Product)
      Forecast Period 2025-2030
      Growth Rate CAGR of 13.2% from 2025 to 2030
      Largest Segment PROSTATE CANCER (Indication)
      Market Size Base Year (Billions) ~USD 3.16 (2025)
      Revenue Forecast (Billions) ~USD 5.87 (2030)
      Segments Covered Product, Target, Indication, End User

      India Radioligand Therapy (RLT) Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Product

      • 225Ac-Psma-617
      • 67Cusarbispsma
      • [Lu-177]-Pnt2002
      • Alphamedix (²¹²Pb-Dotamtate)
      • Alphamedix(²¹²Pb-Dotamtate)
      • Fpi-2265
      • I-131-1095
      • Lutetium-177 Dotatate
      • Lutetium-177 Dotatate (Lutathera)
      • Lutetium177 Vipivotide Tetraxetan
      • Lutetium177 Vipivotide Tetraxetan (Pluvicto)
      • Other Products
      • Radium-223 Dichloride
      • Radium-223 Dichloride (Xofigo)
      • Tlx591 (177Lu Rosopatamab Tetraxetan)

      By Target

      • Other Indications
      • Other Targets
      • Prostate-Specific Membrane Antigen (Psma)
      • Somatostatin Receptor (Sstr)

      By Indication

      • Neuroendocrine Tumor
      • Neuroendocrine Tumors (Nets)
      • Other Indications
      • Prostate Cancer

      By End User

      • Other End Users
      • Specialized Nuclear Medicine Centers
      • Tertiary Care Academic/ Comprehensive Cancer Centers

      INDIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035

      Segment2023202420252026202720282035CAGR (%)
      OTHER END USERS2.841.891.94.646.638.4138.3835.1
      SPECIALIZED NUCLEAR MEDICINE CENTERS3.822.552.586.349.111.654.5135.7
      TERTIARY CARE ACADEMIC/ COMPREHENSIVE CANCER CENTERS8.745.725.6413.5719.0723.7795.8932.7
      TOTAL15.3910.1710.1224.5534.8143.78188.7934

      Target Audience

      • Pharmaceutical and Biotech Companies : Manufacturers and developers of radioligand therapies require India-specific market data to evaluate market entry feasibility, assess competitive positioning, identify partnership opportunities, and develop localized commercialization strategies.
      • Healthcare Investors and Private Equity : Investment firms evaluating opportunities in India's oncology and nuclear medicine sectors need comprehensive market intelligence to assess growth potential, identify acquisition targets, and make informed capital allocation decisions.
      • Hospital Networks and Cancer Centers : Leading healthcare providers and oncology centers require market insights to evaluate RLT service expansion feasibility, understand patient demand trends, benchmark against peers, and plan infrastructure investments.
      • Medical Device and Equipment Suppliers : Manufacturers of nuclear medicine equipment, imaging systems, and radiopharmaceutical production infrastructure need India-specific demand forecasts to guide product development, market expansion, and sales strategy optimization.
      • Healthcare Consultants and Policy Advisors : Consulting firms and healthcare policy organizations require detailed India market analysis to advise clients on market opportunities, regulatory navigation, reimbursement strategies, and healthcare infrastructure development initiatives.

      Reasons to Buy this Report

      • Quantified Market Sizing for India : Access precise market valuation data specific to India's RLT sector, including baseline 2025 estimates and 2030 forecasts, enabling accurate financial planning and investment decisions tailored to the Indian market landscape.
      • India-Specific Growth Drivers Analysis : Understand the unique factors propelling India's RLT market expansion, including cancer epidemiology, healthcare infrastructure investments, regulatory environment, and clinical adoption patterns distinct to the Indian healthcare system.
      • Competitive Landscape and Market Entry Strategy : Identify key players, market gaps, and strategic opportunities specific to India's RLT ecosystem, enabling informed market entry strategies, partnership identification, and competitive positioning within the Indian oncology market.
      • Regional Infrastructure and Capability Assessment : Evaluate India's nuclear medicine infrastructure, radiopharmaceutical production capacity, and clinical facility distribution to assess market readiness, identify investment opportunities, and optimize distribution strategies.
      • Reimbursement and Regulatory Pathway Insights : Gain detailed intelligence on India's regulatory framework, reimbursement mechanisms, pricing dynamics, and clinical trial landscape to navigate market entry, ensure compliance, and optimize commercial strategies.

      Frequently asked questions

      What is the projected market size for radioligand therapy in India by 2030?

      India's radioligand therapy market is projected to reach USD 14.21 million by 2030, representing significant growth from the nascent market baseline in 2025.

      What are the primary drivers of RLT adoption in India?

      India's RLT market growth is driven by rising cancer incidence, expanding healthcare infrastructure, increasing precision oncology awareness, and regulatory support for nuclear medicine therapies.

      Which cancer indications are driving RLT demand in India?

      Neuroendocrine tumors, prostate cancer, and gastroenteropancreatic neuroendocrine tumors are key indications driving India's radioligand therapy adoption and clinical trial expansion.

      What regulatory approvals are required for RLT in India?

      India's CDSCO oversees radioligand therapy approvals, requiring compliance with radiopharmaceutical manufacturing standards, clinical trial protocols, and radiation safety guidelines.

      How is India developing radiopharmaceutical manufacturing capacity for RLT?

      India's healthcare institutions and pharmaceutical companies are investing in cyclotron infrastructure and radiopharmaceutical production facilities to support domestic RLT availability and reduce import dependency.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global radioligand therapy market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the radioligand therapy market. The secondary sources used for this study include World Health Organization (WHO), National Institutes of Health (NIH), National Cancer Institute (NCI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Centers for Drug Evaluation and Research (CDER), International Society for Pharmaceutical Engineering (ISPE), Innovative Medicines Initiative (IMI), Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Association of Nuclear Medicine (EANM), PubMed, National Center for Biotechnology Information (NCBI), International Trade Centre (ITC), Press Releases, Company Websites, and Magazines & Proprietary Databases. Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis.

      Primary Research

      A comprehensive primary research was undertaken following an initial assessment of the global radioligand therapy market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

      The following is a breakdown of the primary respondents:

      Radioligand Therapy Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both bottom-up and top-down approaches were used to estimate and validate the total size of the radioligand therapy market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • A list of the major global players operating in the radioligand therapy market was generated.
      • The revenues generated from their radioligand therapy product have been determined through annual reports and secondary sources (including paid databases)
      • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
      • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

      Radioligand Therapy Market : Top-Down and Bottom-Up Approach

      Radioligand Therapy Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Radioligand therapy (RLT) is a form of precision oncology that delivers targeted radiation to cancer cells while minimizing damage to healthy cells. Once administered, the ligand guides the radioactive payload directly to cancer cells, allowing for precise radiation delivery while minimizing damage to surrounding healthy tissues.

      Stakeholders

      • Pharmaceutical Companies
      • National and Regional Research Boards & Organizations
      • Research & Development Companies
      • Contract Research Organizations (CROs)
      • Contract Manufacturing Organizations (CMOs)
      • Contract Research Development & Manufacturing Organizations (CRDMOs)
      • Medical Device Companies
      • Biotechnology Companies
      • Research Laboratories & Academic Institutes
      • Market Research & Consulting Firms
      • Regulatory Bodies

      Report Objectives

      • To define, describe, and forecast the radioligand therapy market based on product, target, indication, end user, and region
      • To provide detailed information on the significant factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the radioligand therapy market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To profile the key players in the global radioligand therapy market and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze competitive developments such as product approvals & launches, expansions, agreements, and collaborations in the radioligand therapy market
      • To benchmark players within the radioligand therapy market using the company evaluation matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

       

      Get the Full Radioligand Therapy (RLT) Market Report

      Full forecast, segment splits, and company analysis for all Radioligand Therapy (RLT) Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status